Mounjaro levels: what each dose strength means for your treatment

Where the trial data on Mounjaro levels comes from

The clearest picture of what individual dose levels do comes from SURMOUNT-1, the pivotal 72-week trial that tested tirzepatide at 5 mg, 10 mg and 15 mg against placebo in adults with obesity but without type 2 diabetes. Average weight reduction was roughly 15% at 5 mg, around 19.5% at 10 mg and approximately 20–21% at 15 mg. Those aren't ceiling values, some participants lost considerably more. What the trial confirmed is a dose-response relationship: higher levels, on average, produced greater weight loss.

The 2.5 mg starting level was not tested as a maintenance dose and does not appear in the long-term results tables; it functions as a four-week settling period before the first therapeutic step up to 5 mg. NICE's appraisal of tirzepatide (TA1026, published December 2024) draws on this evidence to support its recommendation for adults with BMI 35 or above alongside at least one weight-related condition, and acknowledges that lower thresholds apply for certain ethnic backgrounds under UK guidance.

One practical detail worth knowing: the SURMOUNT-1 trial involved 2,539 participants, a number large enough to give the results statistical weight but not the tens of thousands sometimes cited loosely in summaries. The wider tirzepatide clinical programme, including the SURPASS diabetes trials, involved more than 10,000 participants in total.

What the six Mounjaro levels actually do at each stage

The 2.5 mg pen's job is adjustment. Side effects from tirzepatide are mostly gastrointestinal (nausea, changes in bowel habit, reduced appetite) and starting low gives the body time to settle before any therapeutic dose begins. It is not ineffective; some people notice reduced hunger almost immediately. But the evidence for meaningful weight loss starts accumulating from 5 mg onwards.

From 5 mg through 15 mg, each level represents a greater degree of activation at both the GIP and GLP-1 receptors that tirzepatide targets. Practically, that tends to translate into stronger appetite suppression, more pronounced gastric slowing and (in trials) progressively greater average weight reduction. The increases happen in 4-week steps, though your prescriber can hold you at a given level for longer if needed. There is no obligation to reach 15 mg. If 10 mg is working well and you're tolerating it comfortably, staying there is a legitimate clinical decision.

If you're thinking about what tirzepatide costs at different points in treatment, our Mounjaro pricing page explains how the UK private market works and what a transparent price actually includes. Worth reading before comparing quotes online.

How dose decisions are made, and who makes them

The prescriber, not the patient, decides whether to move to the next level. At nume, a GPhC-registered Independent Prescriber personally reviews each consultation; your consultation isn't processed by software. Before any dose increase, evidence of your current weight and how you're tolerating the existing level is assessed. That's not a formality, it's the same standard applied to transfer patients arriving from other providers.

Several factors influence the pace of titration: how well you're tolerating side effects, whether weight loss is progressing, and any relevant medical history. People sometimes ask whether staying at a lower level is "failing" the treatment. It isn't. The clinical goal is the highest dose that produces meaningful results at acceptable tolerability, which differs from person to person. If weight loss stalls before you've reached the maximum, a prescriber may recommend moving up. If side effects are limiting quality of life, the right call might be to hold.

Questions about hormonal effects at different levels (such as how tirzepatide interacts with cortisol or oestrogen) come up regularly too. Our pages on Mounjaro and cortisol levels and how Mounjaro affects oestrogen look at what the current evidence does and doesn't show.

Practical considerations across the dose schedule

Each KwikPen delivers four doses at the same strength, so you use one pen per month. That matters logistically: if you order by midday on a weekday and your prescription is approved, the pen dispatches the same day and arrives with DPD the next working morning, useful if your stock runs low mid-week with a busy schedule.

Storage is consistent across all six levels: refrigerate at 2–8°C. There is a limited window during which pens can be kept at room temperature, but the exact duration is set out in the Patient Information Leaflet accompanying your pen, and that's where you should check it rather than relying on a summary figure online.

Energy levels and fatigue are a common question during titration, particularly in the first few weeks at a new level. The Mounjaro and energy levels page covers what's known about this and when it typically settles. Separately, some patients ask about calcium, given that diet quality can shift on treatment; the Mounjaro and calcium levels page addresses that specifically.

For a full overview of how tirzepatide works and what the treatment involves, the tirzepatide information page is a good starting point, and the Mounjaro treatment page covers what private treatment through a GPhC-registered pharmacy looks like from consultation to delivery. If you have specific questions about your situation, the contact page reaches our clinical team directly, or you can read about the people behind the service on the clinical team profile.